EDISON EQUITY RESEARCH - AETERNA ZENTARIS

Edison Investment Research: Aeterna Zentaris - Nearing transition to a commercial story

Aeterna Zentaris is poised to transition to a commercial entity in 2015. Macrilen has an FDA PDUFA date of 5 November in the evaluation of adult growth hormone deficiency (AGHD), a category currently dominated by insulin tolerance tests. Aeterna plans to launch Macrilen in January 2015, if approved. With $39m in cash at 30 June 2014, Aeterna is funded through the reporting of key interim data from its Phase III study of zoptarelin doxorubicin for advanced endometrial cancer, expected near mid-2015.

Aeterna Zentaris is a specialty biopharmaceutical firm developing therapies in oncology and endocrinology. Its lead compounds include zoptarelin doxorubicin, in Phase III trials for endometrial cancer, and Macrilen (macimorelin), under NDA review for adult growth hormone deficiency assessment.

Follow the link to view the full report: http://www.edisoninvestmentresearch.com/research/report/aeterna-zentaris2

Click here to view all of Edison Investment Research's published reports.